Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Assets (2020 - 2026)

Bioventus filings provide 6 years of Assets readings, the most recent being $683.6 million for Q4 2025.

  • On a quarterly basis, Assets fell 6.1% to $683.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $683.6 million, a 6.1% decrease, with the full-year FY2025 number at $683.6 million, down 6.1% from a year prior.
  • Assets hit $683.6 million in Q4 2025 for Bioventus, down from $701.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $1.4 billion in Q4 2022 to a low of $643.1 million in Q2 2021.
  • Median Assets over the past 5 years was $793.2 million (2024), compared with a mean of $878.0 million.
  • Biggest five-year swings in Assets: surged 147.92% in 2021 and later tumbled 41.98% in 2023.
  • Bioventus' Assets stood at $1.2 billion in 2021, then rose by 11.97% to $1.4 billion in 2022, then plummeted by 40.92% to $810.9 million in 2023, then decreased by 10.23% to $728.0 million in 2024, then fell by 6.1% to $683.6 million in 2025.
  • The last three reported values for Assets were $683.6 million (Q4 2025), $701.6 million (Q3 2025), and $706.8 million (Q2 2025) per Business Quant data.